Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE